Correction

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

N Engl J Med 2007; 357:100July 5, 2007

Article

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes (Original Article, N Engl J Med 2007:356;2457 - 2471) . The fifth and sixth sentences of the first paragraph of the Methods section (page 2458) should have read “Of the remaining 42 studies, 38 reported at least one myocardial infarction, and 23 reported at least one death from cardiovascular causes. In these trials, 15,565 patients were randomly assigned to regimens that included rosiglitazone, and 12,282 were assigned to comparator groups with regimens that did not include rosiglitazone.” The last sentence of the third paragraph of the Methods section should have read “In this group of 35 trials, 9507 patients were randomly assigned to receive rosiglitazone, and 5960 patients were assigned to receive various comparator drugs.” In Table 1 (page 2461), the subtotal in the rosiglitazone group should have been 9507 rather than 9502, and the subtotal in the control group should have been 5960 rather than 5961, which brings the total number of patients in the rosiglitazone group to 15,565 and the total in the control group to 12,282. In Table 4 (page 2468), the rate of myocardial infarction in the small trials combined should have read “44/10,285” for the rosiglitazone group and “22/6106” for the control group. The rate of myocardial infarction for the ADOPT trial should have read “41/2895 (1.42)” for the control group. Death from cardiovascular causes in the small trials combined should have read “25/6845 (0.36)” for the rosiglitazone group and “7/3980 (0.18)” for the control group, death from cardiovascular causes in the DREAM trial should have read “12/2635 (0.46)” for the rosiglitazone group, and death from cardiovascular causes in the ADOPT trial should have read “5/2895 (0.17)” for the control group. The text and tables have been corrected on the Journal's Web site at www.nejm.org.

Citing Articles (5)

Citing Articles

1. 1

   William H. Herman, John B. Buse, Richard F. Arakaki, Kathleen M. Dungan, Honghua H. Jiang, Jennie G. Jacobson, Jessie L. Fahrbach. (2011) Concomitant Oral Antihyperglycemic Agent Use and Associated Treatment Outcomes After Initiation of Insulin Therapy. Endocrine Practice 17:4, 563-567
   CrossRef

2. 2

   Stephen A. Brietzke. (2010) A Personalized Approach to Metabolic Aspects of Obesity. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:5, 499-510
   CrossRef

3. 3

   Luigi F. Meneghini, Louise Traylor, Sherwyn L. Schwartz. (2010) Improved Glycemic Control with Insulin Glargine Versus Pioglitazone as Add-On Therapy to Sulfonylurea or Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus. Endocrine Practice 16:4, 588-599
   CrossRef

4. 4

   L. Mateos Polo, M.J. García Rodríguez, N. Cubino Bóveda. (2008) Guía de utilización de antidiabéticos orales: criterios de inicio, seguimiento, combinación y sustitución. Medicine - Programa de Formación Médica Continuada Acreditado 10:18, 1209-1212
   CrossRef

5. 5

   L. Mateos Polo, J.C. Hernández Criado, N. Cubino Bóveda, A. García Mingo. (2008) Antidiabéticos orales. Medicine - Programa de Formación Médica Continuada Acreditado 10:18, 1188-1194
   CrossRef